Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting
出版年份 2015 全文链接
标题
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 113, Issue 7, Pages 1027-1034
出版商
Springer Nature
发表日期
2015-09-11
DOI
10.1038/bjc.2015.329
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma
- (2015) Hidetoshi Hayashi et al. Oncotarget
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
- (2014) B P Schneider et al. BRITISH JOURNAL OF CANCER
- Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
- (2014) M. Chiron et al. MOLECULAR CANCER THERAPEUTICS
- FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
- (2013) T. Brodowicz et al. ANNALS OF ONCOLOGY
- Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
- (2013) F Joulain et al. BRITISH JOURNAL OF CANCER
- Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy
- (2013) A Necchi et al. BRITISH JOURNAL OF CANCER
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Aflibercept
- (2013) K. K. Ciombor et al. CLINICAL CANCER RESEARCH
- Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab
- (2013) Javier Sastre et al. Clinical Colorectal Cancer
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials
- (2013) Fausto Petrelli et al. MEDICAL ONCOLOGY
- Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
- (2013) Yingmiao Liu et al. Cancer Medicine
- Young Oncologists
- (2012) ANNALS OF ONCOLOGY
- Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
- (2012) A Abajo et al. BRITISH JOURNAL OF CANCER
- Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
- (2012) C. Daly et al. CANCER RESEARCH
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) V. Boige et al. ONCOLOGIST
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
- (2010) V Goede et al. BRITISH JOURNAL OF CANCER
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
- (2010) J. L. Brown et al. MOLECULAR CANCER THERAPEUTICS
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
- (2009) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
- (2008) A. M. Schultheis et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started